Grammy and Emmy award winner, and Tony award nominee, the multi-talented musician, singer and actor Harry Connick, Jr. and his wife of 24 years and former model, Jill Connick, recently marked the fifth anniversary of Jill’s recovery from breast cancer. As Jill credits timely screening and early detection for being a cancer survivor today, she is joining Harry to share their experience and to raise awareness of another cancer for which timely screening is critical: colon cancer.* Their efforts will support The New 50, a public education campaign sponsored by Exact Sciences, that debuts today during Colorectal Cancer Awareness Month. The initiative aims to encourage people 50 and older to talk with their healthcare provider about screening, including the modern, noninvasive options that can fit into any schedule of this busy, on-the-go “new 50” generation.
To view the multimedia release go to:
https://www.multivu.com/players/English/8280451-harry-and-jill-connick-colon-cancer-screening-the-new-50/
Significant advances toward cures for blood cancer patients, many of which were funded by The Leukemia & Lymphoma Society (LLS) over the past 65 years, are among the dramatic highlights featured in Ken Burns presents CANCER: THE EMPEROR OF ALL MALADIES, a film by Barak Goodman, to air on PBS stations nationwide from March 30-April 1. The documentary series is based on the Pulitzer Prize-winning book by Siddhartha Mukherjee, MD, The Emperor of All Maladies: A Biography of Cancer.
LLS has been a driving force behind treatment breakthroughs for patients with blood cancers, including leukemia, lymphoma and myeloma. As the world’s largest voluntary health agency dedicated to finding cures for blood cancer patients, LLS has invested more than $1billion in research to advance lifesaving treatments and cures.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7409151-lls-cancer-research-pbs-series/
Zensun Sci & Tech, Ltd., a biopharmaceutical company based in Shanghai and San Diego, announced today positive results of four completed Phase 2 clinical trials including three double-blind, placebo-controlled studies conducted in China and Australia and interim results from the United States Phase 2 trial for Zensun’s innovative “first-in-class” anti-heart failure drug, Neucardin™.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61677-zensun-completes-clinical-trials-of-neucardin-treatment-of-heart-failure
Galderma, a leading global pharmaceutical company exclusively focused on dermatology, today announced that the European Commission has granted Marketing Authorisation in Europe for Mirvaso® (brimonidine) 3 mg/g gel.
Mirvaso® is an alpha-2 adrenergic receptor agonist that acts rapidly and can last for up to 12 hours.1 It is indicated for the symptomatic treatment of facial erythema (redness) of rosacea in adult patients.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65011-mirvaso-first-and-only-treatment-rosacea
Syneron Medical Ltd., the leading global aesthetic device company, announced to a group of international media its new activities and enhanced global commitment to developing the non-invasive body shaping market, one of the fastest growing segments in the global aesthetic medical device market. The press conference took place at the Academy of Medical Sciences in London, just prior to the opening of the BODY Conference and Exhibition, which took place in London on November 3-4, 2012 and for which Syneron was the main sponsor.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58631-body-shaping-by-syneron
Northwestern Mutual, presenting sponsor of the Rose Bowl Game, today announced that its float in the 127th Rose Parade presented by Honda in Pasadena on Jan. 1, 2016, will support the fight against childhood cancer.
The theme of this year’s parade is Find Your Adventure. Northwestern Mutual will dedicate its float design to the greatest adventure and dream of 13-year-old Peyton Richardson of Sugar Land, Texas, who is in treatment for acute lymphocytic leukemia (ALL). Northwestern Mutual is committed to raising awareness, accelerating the search for cures to childhood cancer and providing support to families battling the disease.
Peyton, an aspiring ballerina, would like to see the performances of the distinguished ballet companies of the world and have a ballet lesson with one of their principal dancers. Peyton’s adventure will be brought to life in flowers by Fiesta Parade Floats.
To view the multimedia release go to:
http://www.multivu.com/players/English/7422154-northwestern-mutual-rose-bowl/
Following FDA approval of the AspireSR® generator for the VNS Therapy® system in June 2015, more than a thousand patients with drug-resistant epilepsy across the United States have received this new treatment option. Many of these patients are experiencing benefits which have positively impacted their lives – and are sharing their stories during Epilepsy Awareness Month with the hope of encouraging others to seek new treatments for drug-resistant epilepsy. Numerous hospitals nationwide have begun providing the AspireSR device to patients with drug-resistant epilepsy – a condition that affects as many as one-third of people with epilepsy, causing them to have seizures in spite of treatment with antiepileptic medications.
The VNS Therapy system is a minimally invasive option in which a medical device is placed under the skin in the upper chest area during an outpatient procedure. The device sends mild electrical pulses through the vagus nerve to areas of the brain known to be associated with seizures. The new AspireSR generator takes the VNS Therapy technology a step further – detecting relative heart-rate increases that are often associated with seizures in people with epilepsy and providing responsive stimulation in an attempt to stop and shorten seizures and improve recovery.
To view the multimedia release go to:
http://www.multivu.com/players/English/7651751-livanova-aspiresr-treatment/
The ImplantCenter has recently opened the brand-new operating room suited for more complex treatments. This comes alongside numerous additions such as the launch of the four cosy apartments to rest after treatments at the clinic and an implant education facility to expand their services further. These expansions are part of constant improvements that have been occurring for the last 15 years, alongside high quality service.
The area of the clinic has increased by ten-fold to approximately 1800 m2 during the years. Moreover, the oral surgery division was opened in 2015, so eight dental treatment rooms and four oral surgery rooms are now in place today. All of the surgery rooms can serve ambulatory oral surgery treatments. The ImplantCenter is unique in Hungarian private dentistry because they can implement more complex treatments in the framework of one-day oral surgery procedure. This is due to the big and fully equipped operating room opened in November 2017. As part of the service, the ImplantCenter offers one and two-bed private rooms with medical supervision to their patients after each surgery.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8274651-implantcenter-hungarian-dental-service/
The Prostate Cancer Foundation (PCF) and Major League Baseball (MLB) are once again teaming up to hit home runs for prostate cancer research and encourage fans to “Keep Dad in the Game” as part of the yearly celebration of Father’s Day and annual Home Run Challenge.
This year Joe Torre, MLB’s Chief Baseball Officer, Hall of Famer and prostate cancer survivor, encourages baseball fans everywhere to support PCF’s efforts to end prostate cancer by delivering an important public service announcement, “to step up to the plate, help save lives and get one step closer to finding a cure.”
“Joe has been a great partner in our progress toward improved treatment outcomes and an eventual cure,” said PCF Founder and Chairman Mike Milken. “His work as well as those by MLB and all 30 Clubs has helped us raise more than $45 million for research programs that are saving thousands of lives.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7729251-pcf-and-mlb-prostate-home-run-challenge/
Denny’s, one of America’s largest full-service restaurant chains, today announced its commitment to sourcing and serving 100 percent cage-free eggs in all of its U.S. restaurants by 2026. Denny’s is the first within the family dining segment to commit to 100% cage-free eggs, underlining the brand’s dedication to the humane treatment of animals within its supply sourcing and its ongoing focus on quality, flavor and guest satisfaction.
“We believe our guests care about how their food is sourced and so do we. For more than 60 years, we have listened to our guests to understand what they care about the most, without sacrificing on quality, taste or value,” said John Miller, Denny’s president and chief executive officer. “The humane treatment of animals remains an important part of our brand’s sourcing strategy, and our commitment to this transition underscores our confidence in the ethical evolution of supplier capabilities.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7731351-denny-s-commits-cage-free-eggs/
When a child is diagnosed with cancer, their family is presented with treatment options – often a combination of surgery, radiation and chemotherapy. Radiation and chemotherapy have been used to treat kids’ cancers for more than 50 years and often come with long-term late effects including secondary cancers, heart damage and cognitive issues. Often a child’s best chance at survival is a clinical trial which offers them the newest treatment options available.
In recognition of Childhood Cancer Awareness Month, the St. Baldrick’s Foundation will highlight the critical need to fund lifesaving research and share stories of kids affected by cancer – like Micah, who is alive today because there was a clinical trial available.
To view the multimedia release go to:
https://www.multivu.com/players/English/8284352-st-baldricks-foundation-conquer-childhood-cancers/
Findings from continued clinical studies of investigational chimeric antigen receptor (CAR) therapy, CTL019, demonstrate its potential role in the treatment of certain types of lymphocytic leukemia. In one long-term study of pediatric patients with acute lymphoblastic leukemia (ALL), results showed that 36 of 39 pediatric patients with relapsed/refractory (r/r) ALL, or 92%, experienced complete remissions (CR) with CTL0191.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7393851-novartis-new-ctl019-clinic-data-acute-lymphoblastic-leukemia/
